Annual Scientific Meeting – Bristol 2026

The theme of the 2026 meeting is Delivering Excellence in an Imperfect World, reflecting our recognition of the challenges faced daily in gynaecological oncology. We will focus on exploring how services under pressure can continue to provide
outstanding patient care.

We are currently working on the programme and already have many distinguished speakers confirmed, reflecting the breadth of expertise of
the many different disciplines within the
Gynaecological Cancer community.

Further details about the speaker and their presentations will be added over the next few months but you can view the proposed outline across all 3 days below.

The full programme for the meeting across all 3 days, including further speaker details, can be viewed here.

The full programme for the meeting across all 3 days, including further speaker details, can be viewed here.

The full programme for the meeting across all 3 days, including further speaker details, can be viewed here.

The full programme for the meeting across all 3 days, including further speaker details, can be viewed here.

The full programme for the meeting across all 3 days, including further speaker details, can be viewed here.

The full programme for the meeting across all 3 days, including further speaker details, can be viewed here.

Payment of Registration Fees
Full payment must be made by credit/debit card at the time of registering. Cards accepted are VISA, Visa Debit and MasterCard. Unfortunately we cannot accept American Express or Maestro.

If you register at the early bird rate, payment must be received in full by the early registration deadline. If payment is not received at this time, your registration rate will automatically be changed to the standard registration rates and the higher fee will apply.

On receipt of your registration form, a confirmation email and receipt will be sent to you by the conference organisers. If you have not received this within 5 working days of registering, please contact the conference organisers by emailing bgcs@in-conference.org.uk.

Cancellation Terms
Notification of cancellation must be sent by email to bgcs@in-conference.org.uk, please ensure you receive an acknowledgment. Cancellations will incur an administration fee of £40.00. If you cancel your place after Wednesday 13th May 2026, the total conference fee will be charged and you will not receive any refund. Name changes however, will be permitted until 24 hours prior to the conference.

By submitting your registration, you agree to the terms of the cancellation policy.

To submit an abstract, you will need to log in to our Online Abstract Submission Site. Once you have created an account, you can log in multiple times to complete your submission(s). Please remember to take a note of your password.

Your abstract needs to follow the BGCS 2026 – Abstract Template provided and in accordance with the Submission Guidelines.

The word limit is 250 words and all abstracts must be written and presented in English. Please do not add any images or table; use only plain text and follow the headings in the document as a guide for your abstract structure. Once your abstract is complete, save the document; you will be asked to upload it during the submission process.

You can choose to submit an abstract for consideration as an Oral Presentation, Short Oral Presentation, Poster Presentation or a Surgical Video Presentation*, under one of the following themes.

• Cervical Cancer
• Clinical Oncology
• Endometrial Cancer
• Genomics
• Medical Oncology
• Nursing
• Ovarian Cancer
• Other Cancers
• Palliative and supportive care
• Pathology
• Rare Tumours
• Screening and Prevention
• Surgical Technique
• Surgical Video
• Survivorship
• Vaginal Cancer
• Vulval Cancer

*  Accepted Surgical Video presentation submissions will be presented as part of the Surgical Video Workshop on Wednesday 24 June.

The deadline to submit an abstract for BGCS 2026 is 23:59 (GMT) on Thursday 26 February 2026. You need to ensure you have completed the submission process before this date. Any submissions in the draft status will not be considered for review.

Authors will be notified about the outcome of their submission(s) during the week commencing Monday 13 April 2026. The notification will be sent to the submitting author only.

Authors will be notified about the outcome of their submission(s) during the week commencing Monday 5 May 2025. The notification will be sent to the submitting author only.

Early registration deadline: Friday 16 May 2025

Church House Westminster
Great Smith Street
London SW1P 3NZ

19:30-23:30

Situated less than 5 minutes from the QEII Centre, Church House will provide a stunning backdrop for the dinner.

Expect drinks, a 3 course dinner and entertainment!

Join us for the drinks reception and hear Stranger Strings: Theremin & Harp Duo play a selection of songs spanning classical, film, television, anime and more.

These striking instruments produce music to delight, mystify and astound in equal measure.

Following dinner, entertainment for the remainder of the evening will be provided by The Soul Agents – a 60s soul band, guaranteed to get any audience on their feet.

Tickets are £65.00 + VAT and will be available to purchase during registration for the main conference.

Places are limited so you are advised to book as soon as possible.

Join us at the foremost scientific gynaecological cancer meeting of the year, the BGCS Annual Scientific Meeting 2026.

We bring together multidisciplinary colleagues involved in screening, prevention, diagnosis and treatment of gynaecological cancers.

The theme for 2026 is Delivering Excellence in an Imperfect World, reflecting our recognition of the challenges faced daily in gynaecological oncology. We will focus on exploring how services under
pressure can continue to provide outstanding patient care.

In addition to specific theme-based sessions, reflecting the breadth of expertise of the many  different disciplines within the Gynaecological Cancer community, the programme will also feature a broad range of parallel sessions.

As well as the established sessions for Clinical Nurse Specialists and Unit Lead Gynaecologists, the 2026 will also incorporate the Clinical Oncology Complex Case Forum and BGCS Research Group
Workshop for the first time.

Why support BGCS 2026?
Gain focused exposure for your brand and make a lasting impression on a highly targeted audience, through our sponsorship opportunities.

Our members consist of medical practitioners, clinical nurse specialists and other allied professionals, including scientists who have an interest in gynaecological cancers. We represent trainees, nurses, unit leads, gynaecological oncology surgeons, medical oncologists, clinical oncologists, pathologists and radiologists and over 400 members regularly attend our annual conference.

Our packages allow you to:

• Promote your organisation’s work through a sponsored symposium
• Align your brand with the Meeting, with advertising options on the mobile app and the digital programme
• Enhance the visibility of your company through branding essential items, including lanyards and conference bags

Exhibit with us
BGCS 2026 also offers the opportunity to generate leads and connect with potential clients, partners and collaborators.

With a presence in our exhibition area, you can:

• Showcase technologies, innovations and solutions to a receptive audience
• Share your latest research and findings
• Explore networking opportunities; nurture existing relationships and form new ones that could translate to long-term business success

Get in touch
Contact us for further information about available sponsorship packages and exhibition opportunities. Secure your spot early and maximise your impact.

BRONZE SPONSORS

For UK Healthcare Professionals Only

GSK Sponsored Symposia 

As one of our Platinum Sponsors, GSK will be offering delegates the opportunity to attend their Symposia, taking place in the Great Hall, on Friday 8^th July.

There is no need to register in advance.

Early Morning Symposium * (breakfast will be provided)
09:00-09:30, Great Hall 

Title
The GARNET trial – reshaping the advanced endometrial treatment landscape.

Welcome and introduction
Dr Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden, London (Chair).

The GARNET trial at ASCO: clinical outcomes from 2 years of survival follow-up
Dr Susana Banerjee

Application of GARNET trial data in clinical practice
Dr John McGrane, Consultant Clinical Oncologist, Royal Cornwall Hospitals, Truro.

Discussion
Moderated by Dr Susana Banerjee

Lunchtime Symposium **
13:10 -13:55, Great Hall

Title
A patient-centric, multidisciplinary approach to decision-making for first-line maintenance therapy in advanced ovarian cancer.

Welcome and introduction
Dr Rowan Miller, Consultant Medical Oncologist, University College London and St Bartholomew’s Hospitals, London, Chair.

Overview of first-line maintenance therapy options in newly diagnosed advanced ovarian cancer
Dr Rowan Miller

Patient case study – Clinical assessment
Ms Lisa Young, Macmillan Lead Gynae Cancer CNS, University Hospital Southampton NHS Foundation Trust, Southampton

PRIME and PRIMA clinical data presentation
Dr Clare Green, Consultant Medical Oncologist, University Hospital Southampton NHS Foundation Trust, Southampton

Patient case study – Patient-centric care
Ms Lisa Young

Multidisciplinary team discussion about patient management

Summary and close
Dr Rowan Miller

*This promotional symposium is funded and organised by GSK and will include information about the GSK-promoted product, ▼JEMPERLI (dostarlimab) 

INDICATION: JEMPERLI (dostarlimab) is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.¹

JEMPERLI Prescribing Information – Great Britain is available here.

JEMPERLI Prescribing Information – Northern Ireland is available here. 

1. JEMPERLI (dostarlimab) Summary of Product Characteristics. 

**This promotional symposium is funded and organised by GSK and will include information about the GSK product, Zejula▼ (niraparib) 

INDICATION: Zejula (niraparib) is indicated as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. Zejula is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.² 

Zejula Prescribing Information – Great Britain is available here.

Zejula Precribing Information – Northern Ireland is available here.

2. Zejula (niraparib) Summary of Product Characteristics. 

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GSK Limited on +44 (0) 800 221 441.

PM-GB-DST-WCNT-220005 | July 2022